The impact of vascular endothelial growth factor-transfected human endothelial cells on endothelialization and restenosis of stainless steel stents

Objectives The purpose of this study was to investigate the effects of gene transfection of endothelial cells with vascular endothelial growth factor (VEGF) on re-endothelialization and inhibiting in-stent restenosis. Methods Stents coated with human umbilical vein endothelial cells (HUVECs) transfected with VEGF 121 were studied both in vitro and in vivo. In vitro studies were performed using a homemade extracorporeal circulation system. In vivo studies were performed using the rabbit abdominal aorta model. Results In vitro studies confirmed that VEGF 121 - transfected cells adhered on the surface of stainless steel stents with over 90% of the surface covered within 24 hours of seeding. In vivo results showed that VEGF 121 -transfected HUVECs-coated stents were covered with seeding cells after implanting, and almost completely covered with cells after stent implantation for 1 week. In contrast, the non-endothelialized areas of bare metal stents and glutin/poly-L-lysine-coated stents were covered at 4 weeks, and the monolayers of cells were not observed, but fragile neointima was found on the surface. After 12 weeks, VEGF 121 -transfected HUVECs-coated stents significantly reduced the neointima area (0.78 ± 0.03 mm 2 ) and stenosis (15.69 ± 2.61%) as compared with those for bare metal stents (neointima area=2.26 ± 0.67 mm 2 ; the percentage of stenosis=47.55 ± 7.10%; P 2 ; the percentage of stenosis=31.37 ± 8.18%; P Conclusion In this small animal study, VEGF transfected human endothelial cells, when coated on stainless steel stents, reduce neointimal hyperplasia, promote endothelialization, and reduce in-stent restenosis. Additional studies with this technology are necessary to determine its ultimate utility in improving stents performance.